Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 19/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 19/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13764416 | 0.97 | ITGB1 (0.46) | ITGB1ITGA4ITGB7NPC1RAB9A | |
| SCHEMBL13764393 | 0.95 | ITGB1 (0.43) | ITGB1ITGA4ITGB7NPC1RAB9A | |
| SCHEMBL13764394 | 0.94 | ITGB1 (0.43) | ITGB1ITGA4ITGB7 | |
| SCHEMBL13764419 | 0.92 | ITGB1 (0.42) | ITGB1ITGA4ITGB7 | |
| SCHEMBL13768574 | 0.92 | NPC1 (0.41) | ITGB1ITGA4NPC1RAB9A | |
| SCHEMBL13768586 | 0.91 | ITGB1 (0.41) | ITGB1ITGA4ITGB7NPC1RAB9A | |
| SCHEMBL13764397 | 0.89 | ITGB1 (0.40) | ITGB1ITGA4ITGB7NPC1RAB9A | |
| SCHEMBL13764403 | 0.88 | ITGB1 (0.41) | ITGB1ITGA4ITGB7 | |
| SCHEMBL13768573 | 0.88 | ITGB1 (0.42) | ITGB1ITGA4NPC1RAB9A | |
| SCHEMBL13768575 | 0.87 | ITGB1 (0.41) | ITGB1ITGA4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090180951-A1 | INHIBITORS OF INTEGRIN VLA-4 | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090180951-A1 | INHIBITORS OF INTEGRIN VLA-4 | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090180951-A1 | INHIBITORS OF INTEGRIN VLA-4 | ITGA1, ITGB1, ITGA4 | ITGB1 2/4885ITGA4 3/4885ITGB7 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.